KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Short-term Investments (2016 - 2023)

Amgen has reported Short-term Investments over the past 15 years, most recently at $1.0 million for Q1 2023.

  • Quarterly results put Short-term Investments at $1.0 million for Q1 2023, down 93.75% from a year ago — trailing twelve months through Mar 2023 was $1.0 million (down 93.75% YoY), and the annual figure for FY2022 was $1.7 billion, up 3391.67%.
  • Short-term Investments for Q1 2023 was $1.0 million at Amgen, down from $1.7 billion in the prior quarter.
  • Over the last five years, Short-term Investments for AMGN hit a ceiling of $18.9 billion in Q1 2019 and a floor of $1.0 million in Q1 2023.
  • Median Short-term Investments over the past 5 years was $2.0 billion (2022), compared with a mean of $4.1 billion.
  • Peak annual rise in Short-term Investments hit 3391.67% in 2022, while the deepest fall reached 99.64% in 2022.
  • Amgen's Short-term Investments stood at $2.9 billion in 2019, then skyrocketed by 52.44% to $4.4 billion in 2020, then tumbled by 98.9% to $48.0 million in 2021, then soared by 3391.67% to $1.7 billion in 2022, then plummeted by 99.94% to $1.0 million in 2023.
  • The last three reported values for Short-term Investments were $1.0 million (Q1 2023), $1.7 billion (Q4 2022), and $2.0 billion (Q3 2022) per Business Quant data.